Taclonex Scalp Side Effects
Generic name: betamethasone / calcipotriene topical
Note: This document contains side effect information about betamethasone / calcipotriene topical. Some of the dosage forms listed on this page may not apply to the brand name Taclonex Scalp.
Some side effects of Taclonex Scalp may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA.
For the Consumer
Applies to betamethasone / calcipotriene topical: topical ointment, topical suspension
Get emergency medical help if you have any of these signs of an allergic reaction while taking betamethasone / calcipotriene topical: hives; difficult breathing; swelling of your face, lips, tongue, or throat.
Stop using betamethasone and calcipotriene and call your doctor at once if you have any of these serious side effects:
-
severe skin irritation on treated areas;
-
worsened symptoms or no improvement in psoriasis;
-
pus, swelling, redness, increased itching, or other signs of skin infection;
-
confusion, thirst, extreme tiredness, lost appetite, weight loss;
-
adrenal insufficiency--nausea, vomiting, lost appetite, tiredness, trouble breathing, joint/muscle pain, feeling light-headed, fainting;
-
Cushing syndrome--weight gain (especially in your face), thinning muscles in your arms or legs, easy bruising, thinning skin, acne, increased facial hair, darkened skin; or
-
high blood sugar (hyperglycemia)--increased urination and thirst, nausea, vomiting.
Less serious side effects of betamethasone / calcipotriene topical may include:
-
burning or mild itching;
-
red or scaly rash;
-
swollen hair follicles; or
-
changes in the color of treated skin areas.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects.
For Healthcare Professionals
Applies to betamethasone / calcipotriene topical: topical ointment, topical suspension
Dermatologic
Common (1% to 10%): Ointment: Pruritus (up to 7.2%), psoriasis (up to 3.4%), skin atrophy (up to 1.9%), folliculitis (up to 1.4%), skin depigmentation (1.4%), scaly rash (1.2%), hand dermatitis (1%); Suspension: Pruritus (3.6%), psoriasis (2.4%), erythema (2.1%), skin irritation (1.4%), folliculitis (up to 1.2%)
Uncommon (0.1% to 1%): Ointment: Erythema (up to 1%), skin irritation (0.4%), papular rash (greater than 0.1% and less than 1%), pustular rash (greater than 0.1% and less than 1%), skin hypopigmentation (greater than 0.1% and less than 1%), telangiectasia (0.1%), skin hyperpigmentation (0.1%); Suspension: Acne (greater than 0.1% and less than 1%), exacerbation of psoriasis (greater than 0.1% and less than 1%), rash (greater than 0.1% and less than 1%), pustular rash (greater than 0.1% and less than 1%)
Rare (less than 0.1%): Ointment: Serious flare-up of psoriasis (at least 1 case)
Postmarketing reports: Ointment: Pustular psoriasis
Nervous system
Common (1% to 10%): Ointment: Headache (2.8%)
Metabolic
Frequency not reported: Hypercalcemia, hypercalciuria
Endocrine
Frequency not reported: Adrenal suppression; Ointment: Hypothalamic-pituitary-adrenal axis suppression
Hypersensitivity
Frequency not reported: Allergic contact dermatitis
Respiratory
Common (1% to 10%): Ointment: Nasopharyngitis (2.3%)
Uncommon (0.1% to 1%): Ointment: Influenza (0.9%), upper respiratory tract infection (0.8%)
Other
Common (1% to 10%): Ointment: Burning sensation (up to 1.4%); Suspension: Burning sensation of skin (1%)
Uncommon (0.1% to 1%): Ointment: Pain (0.3%)
Postmarketing reports: Ointment: Rebound effect
Hematologic
Common (1% to 10%): Ointment: Ecchymosis (1%)
Local
Uncommon (0.1% to 1%): Ointment: Application site pruritus (0.5%)
Ocular
Uncommon (0.1% to 1%): Suspension: Eye irritation (greater than 0.1% and less than 1%)
More Taclonex Scalp resources
- Taclonex Scalp Advanced Consumer (Micromedex) - Includes Dosage Information
- Taclonex Scalp suspension MedFacts Consumer Leaflet (Wolters Kluwer)
- Dovobet Advanced Consumer (Micromedex) - Includes Dosage Information
- Taclonex Prescribing Information (FDA)
- Taclonex ointment MedFacts Consumer Leaflet (Wolters Kluwer)
- Taclonex Consumer Overview
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of information provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.


